Comparison of the Efficacy of New and Conventional Antipsychotic Drugs in the Treatment of Behavioral and Psychological Symptoms of Dementia (Bpsd)

Gareri, Pietro; Cotroneo, Antonino Maria; Lacava, Roberto; Seminara, Giuseppe; Marigliano, Norma; Loiacono, Antonella; Sarro, Giovambattista De

doi:10.1016/j.archger.2004.04.029

Cited by 35 publications

(23 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The oral subchronic treatment with APs for 5 days in SD rats did not induce the appearance of audiogenic seizures following auditory stimulation in comparison with the SD control group, as previously described (data not shown) [26,51,52]. In GEPR-0s, haloperidol, quetiapine, and aripiprazole did not induce any change compared with the control GEPR-0 group at all doses used, whereas clozapine, risperidone, and olanzapine were able to induce the appearance of clonic phase of the audiogenic seizures (score 2-3) at the highest doses used (Fig.…”

Section: Effects Of Daily Antipsychotic Treatment On Severity Of Audimentioning

confidence: 71%

Comparative Analysis of the Treatment of Chronic Antipsychotic Drugs on Epileptic Susceptibility in Genetically Epilepsy-prone Rats

et al. 2015

View full text Add to dashboard Cite

Antipsychotic drugs (APs) are of great benefit in several psychiatric disorders, but they can be associated with various adverse effects, including seizures. To investigate the effects of chronic antipsychotic treatment on seizure susceptibility in genetically epilepsy-prone rats, some APs were administered for 7 weeks, and seizure susceptibility (audiogenic seizures) was evaluated once a week during treatment and for 5 weeks after drug withdrawal. Furthermore, acute and subchronic (5-day treatment) effects were also measured. Rats received haloperidol (0.2-1.0 mg/kg), clozapine (1-5 mg/kg), risperidone (0.03-0.50 mg/kg), quetiapine (2-10 mg/kg), aripriprazole (0.2-1.0 mg/kg), and olanzapine (0.13-0.66 mg/kg), and tested according to treatment duration. Acute administration of APs had no effect on seizures, whereas, after regular treatment, aripiprazole reduced seizure severity; haloperidol had no effects and all other APs increased seizure severity. In chronically treated rats, clozapine showed the most marked proconvulsant effects, followed by risperidone and olanzapine. Quetiapine and haloperidol had only modest effects, and aripiprazole was anticonvulsant. Finally, the proconvulsant effects lasted at least 2-3 weeks after treatment suspension; for aripiprazole, a proconvulsant rebound effect was observed. Taken together, these results indicate and confirm that APs might have the potential to increase the severity of audiogenic seizures but that aripiprazole may exert anticonvulsant effects. The use of APs in patients, particularly in patients with epilepsy, should be monitored for seizure occurrence, including during the time after cessation of therapy. Further studies will determine whether aripiprazole really has a potential as an anticonvulsant drug and might also be clinically relevant for epileptic patients with psychiatric comorbidities.

show abstract

Section: Effects Of Daily Antipsychotic Treatment On Severity Of Audimentioning

confidence: 71%

Comparative Analysis of the Treatment of Chronic Antipsychotic Drugs on Epileptic Susceptibility in Genetically Epilepsy-prone Rats

et al. 2015

View full text Add to dashboard Cite

show abstract

“…The atypical antipsychotics risperidone and olanzapine were shown to be somewhat superior to promazine for the treatment of behavioral and psychological symptoms of dementia, but no specific data on VDB were given (Gareri et al, 2004). According to a retrospective chart review, risperidone was more effective than either haloperidol or olanzapine on behavioral and psychiatric symptoms including VDB, at least in people with dementia, in a mixed group of 202 patients of whom 29 had VDB (Frenchman, 2000).…”

Section: A U T H O R S N U M B E R O F C a S E S I N T E R V E N T I mentioning

confidence: 99%

Vocally disruptive behavior in the elderly: a systematic review

Gunten¹,

Alnawaqil²,

Abderhalden

et al. 2008

Int. Psychogeriatr.

View full text Add to dashboard Cite

show abstract

“…When comparing the body weight effect of SGA or FGA, results are inconclusive: Gareri et al (2004) and Moretti et al (2005) found major effects with OLZ versus FGA; conversely, in the study by Verhey et al (2006), both weight gain and weight loss occurred in similar proportion in patients treated with HAL and OLZ.…”

Section: Body Weightmentioning

confidence: 67%

“…Deberdt et al (2005) found a significant weight gain in patients treated with olanzapine as compared to risperidone (+1.0 kg vs. +0.1 kg over ten weeks; see Table 3). Gareri et al (2004) found weight gain in 32% olanzapine treated patients but not in risperidone and promazine treated patients after eight weeks.…”

Section: Body Weightmentioning

confidence: 95%

A systematic review of metabolic side effects related to the use of antipsychotic drugs in dementia

Atti¹,

Gozzi²,

Zuliani³

et al. 2013

Int. Psychogeriatr.

View full text Add to dashboard Cite

A possible association between antipsychotic drugs use and weight gain might exist, in particular in subjects with mild to moderate dementia whereas no significant effects are demonstrated regarding glucose homeostasis and lipid metabolism. The antipsychotic drugs potential for causing metabolic abnormalities in older patients requires further specifically designed studies. Clinicians must be aware of this possibility even if the shorter periods of treatment administered in late-life might not be as harmful as it is in younger individuals.

show abstract

Comparison of the Efficacy of New and Conventional Antipsychotic Drugs in the Treatment of Behavioral and Psychological Symptoms of Dementia (Bpsd)

Cited by 35 publications

References 22 publications

Comparative Analysis of the Treatment of Chronic Antipsychotic Drugs on Epileptic Susceptibility in Genetically Epilepsy-prone Rats

Comparative Analysis of the Treatment of Chronic Antipsychotic Drugs on Epileptic Susceptibility in Genetically Epilepsy-prone Rats

Vocally disruptive behavior in the elderly: a systematic review

A systematic review of metabolic side effects related to the use of antipsychotic drugs in dementia

Contact Info

Product

Resources

About